Madrigal Pharmaceuticals, Inc. MDGL
11 trading plans running, 29 Form 144 notices for $96.7M
10-Q, 10-K and Form 144What MDGL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Sep 2, 2025 to Mar 1, 2028. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Rebecca Taub, M.D. Director |
Adopted 10b5-1 plan | Aug 28, 2026 | 10-Q Nov 3, 2026 | ||
| Mardi Dier Chief Financial Officer |
Adopted 10b5-1 plan | Aug 4, 2026 | 10-Q Nov 3, 2026 | ||
| Carole Huntsman Chief Commercial Officer |
Adopted 10b5-1 plan | Jul 31, 2026 | 10-Q Nov 3, 2026 | ||
| Shannon Kelley Chief Legal Officer |
Adopted 10b5-1 plan | Jul 31, 2026 | 10-Q Nov 3, 2026 | ||
| William Sibold Chief Executive Officer and Director |
Adopted 10b5-1 plan | Jun 5, 2026 | 10-Q Jul 30, 2026 | ||
| David Soergel, M.D. Chief Medical Officer |
Adopted 10b5-1 plan | Mar 2, 2026 | 10-Q May 6, 2026 | ||
| Richard Levy, M.D. Director |
Adopted 10b5-1 plan | Feb 20, 2026 | 10-Q May 6, 2026 | ||
| Paul Friedman, M.D. Director |
Adopted 10b5-1 plan | Sep 10, 2025 | 10-Q Nov 4, 2025 | ||
| Rebecca Taub, M.D. Senior Scientific and Medical Advisor and Director |
Adopted 10b5-1 plan | Sep 10, 2025 | 10-Q Nov 4, 2025 | ||
| Mardi Dier Chief Financial Officer |
Adopted 10b5-1 plan | Sep 2, 2025 | 10-Q Nov 4, 2025 | ||
| Richard Levy, M.D. Director |
Adopted 10b5-1 plan | Aug 14, 2025 | 10-Q Nov 4, 2025 | ||
| Richard Levy, MD Director |
Ended plan | Jun 16, 2025 | 10-K Feb 28, 2024 | ||
| Becky Taub, MD President of R&D, CMO and Director |
Ended plan | Apr 3, 2025 | 10-K Feb 28, 2024 | ||
| Paul Friedman, MD Director |
Ended plan | Apr 3, 2025 | 10-K Feb 28, 2024 | ||
| James Daly Director |
Ended plan | Jun 27, 2024 | 10-K Feb 28, 2024 | ||
| Kenneth Bate Director |
Ended plan | Jun 27, 2024 | 10-K Feb 28, 2024 | ||
| Fred B. Craves, Ph.D. Director |
Adopted 10b5-1 plan | Dec 15, 2023 | 10-Q Aug 7, 2024 | ||
| Fred B. Craves, Ph.D. Director |
Adopted 10b5-1 plan | Dec 15, 2023 | 10-Q May 7, 2024 | ||
| Richard Levy, MD Director |
Adopted 10b5-1 plan | Nov 30, 2023 | 10-Q Oct 31, 2024 | ||
What the company wroteThe following table shows the number of shares of our common stock subject to the current Rule 10b5-1 trading arrangements of our Section 16 officers and directors in place as of October 28, 2024: Name of Director or Section 16 Officer Title of Director or Section 16 Officer Date of Adoption, Modification, or Termination Duration of the Plan Aggregate Number of Shares of Common Stock that may be Sold under the Plan Richard Levy, MD Director 11/30/2023 June 16, 2025 15,000 | |||||
| Richard Levy, MD Director |
Adopted 10b5-1 plan | Nov 30, 2023 | 10-Q Aug 7, 2024 | ||
| Richard Levy, MD Director |
Adopted 10b5-1 plan | Nov 30, 2023 | 10-Q May 7, 2024 | ||
| Bill Sibold Chief Executive Officer |
Adopted 10b5-1 plan | – | 10-K Feb 26, 2025 | ||
| Carole Huntsman Chief Commercial Officer |
Adopted 10b5-1 plan | – | 10-K Feb 26, 2025 | ||
| Mardi Dier Chief Financial Officer |
Adopted 10b5-1 plan | – | 10-K Feb 26, 2025 | ||
| Paul Friedman, M.D., Director |
Adopted 10b5-1 plan | – | 10-Q May 1, 2025 | ||
| Rebecca Taub, M.D., Senior Scientific and Medical Advisor and Director |
Adopted 10b5-1 plan | – | 10-Q May 1, 2025 | ||
| Shannon Kelley General Counsel |
Adopted 10b5-1 plan | – | 10-K Feb 26, 2025 | ||
Show the other 19 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 6, 2026 | SHANNON KELLEY Officer |
1,077 | $431K |
| Sep 28, 2026 | PAUL FRIEDMAN Director |
50,000 | $25.8M |
| Sep 11, 2026 | WILLIAM SIBOLD Director, Officer |
5,221 | $2.8M |
| Sep 9, 2026 | William John Sibold Officer and Director |
6,362 | $3.4M |
| Aug 20, 2026 | Shannon Kelley Officer |
664 | $337K |
| Jul 20, 2026 | William Sibold Officer and Director |
2,500 | $1.4M |
| Jun 1, 2026 | DAVID SOERGEL Officer |
1,042 | $518K |
| May 22, 2026 | RICHARD LEVY Director |
5,682 | $2.9M |
| May 18, 2026 | David Soergel Officer |
844 | $442K |
| Mar 6, 2026 | MARDI DIER Officer |
1,336 | $587K |
| Mar 6, 2026 | Mardi Dier Officer |
646 | $284K |
| Mar 6, 2026 | William Sibold Officer and Director |
1,663 | $731K |
| Mar 6, 2026 | Shannon Kelley Officer |
360 | $158K |
| Mar 6, 2026 | Carole Huntsman Officer |
419 | $184K |
| Mar 6, 2026 | Rebecca Taub Director |
491 | $216K |
| Mar 2, 2026 | Mardi Dier Officer |
1,183 | $511K |
| Jan 26, 2026 | CAROLE A HUNTSMAN Officer |
570 | $274K |
| Jan 26, 2026 | Carole Huntsman Officer |
340 | $163K |
| Jan 26, 2026 | William Sibold Officer and Director |
1,577 | $758K |
| Jan 26, 2026 | Rebecca Taub Director |
647 | $311K |
| Jan 20, 2026 | SHANNON KELLEY Officer |
429 | $215K |
| Jan 20, 2026 | Shannon Kelley Officer |
263 | $132K |
| Jan 20, 2026 | Rebecca Taub Director |
2,238 | $1.1M |
| Jan 9, 2026 | REBECCA A TAUB Director |
18,650 | $10.4M |
| Dec 10, 2025 | PAUL FRIEDMAN Director |
49,600 | $27.5M |
| Dec 10, 2025 | REBECCA A TAUB Director |
18,650 | $10.3M |
| Dec 4, 2025 | William John Sibold Officer and Director |
2,400 | $1.4M |
| Dec 2, 2025 | MARDI C DIER Officer |
4,173 | $2.4M |
| Nov 21, 2025 | Carole Huntsman Officer |
1,958 | $1.1M |
Show the other 21 notices
From the Form 144 XML filed with the SEC, since Nov 21, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDGL/export.csv") into a cell.